File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Lamivudine therapy for chronic hepatitis B

TitleLamivudine therapy for chronic hepatitis B
Authors
KeywordsHepatitis B
Lamivudine
Hepatitis B virus (HBV) DNA
Hepatitis B e antigen (HBeAg)
Antiviral
Issue Date2010
PublisherSan Lucas Medical Ltd.. The Journal's web site is located at http://www.agh.sanlucasmedical.com/About_the_Journal-120
Citation
The Annals of Gastroenterology & Hepatology, 2010, v. 1 n. 1, p. 63-70 How to Cite?
AbstractLamivudine was introduced as an antiviral for chronic hepatitis B over a decade ago. Its role in the management of CHB has been constantly changing. Lamivudine has proven benefit in both hepatitis B e antigen‐positive and ‐negative patients. It is able to alter the clinical outcomes of chronic hepatitis B patients and reduce the rates of cirrhotic complications and hepatocellular carcinoma. However, it has a low genetic barrier towards resistance; lamivudine resistance is a continuing and challenging problem in the management of chronic hepatitis B. Lamivudine also has a role in combination therapy, pre‐emptive therapy for patients receiving chemotherapy, and treatment in other special population groups. Although currently not a first‐line treatment for chronic hepatitis B, there are certain patient subgroups that may benefit from lamivudine therapy. With the extensive experience of widespread use of lamivudine, the long‐term safety of lamivudine has been well established.
Persistent Identifierhttp://hdl.handle.net/10722/181681
ISSN

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorFung, Jen_US
dc.contributor.authorYuen, RMFen_US
dc.date.accessioned2013-03-19T03:53:48Z-
dc.date.available2013-03-19T03:53:48Z-
dc.date.issued2010en_US
dc.identifier.citationThe Annals of Gastroenterology & Hepatology, 2010, v. 1 n. 1, p. 63-70en_US
dc.identifier.issn2043-0221en_US
dc.identifier.urihttp://hdl.handle.net/10722/181681-
dc.description.abstractLamivudine was introduced as an antiviral for chronic hepatitis B over a decade ago. Its role in the management of CHB has been constantly changing. Lamivudine has proven benefit in both hepatitis B e antigen‐positive and ‐negative patients. It is able to alter the clinical outcomes of chronic hepatitis B patients and reduce the rates of cirrhotic complications and hepatocellular carcinoma. However, it has a low genetic barrier towards resistance; lamivudine resistance is a continuing and challenging problem in the management of chronic hepatitis B. Lamivudine also has a role in combination therapy, pre‐emptive therapy for patients receiving chemotherapy, and treatment in other special population groups. Although currently not a first‐line treatment for chronic hepatitis B, there are certain patient subgroups that may benefit from lamivudine therapy. With the extensive experience of widespread use of lamivudine, the long‐term safety of lamivudine has been well established.-
dc.languageengen_US
dc.publisherSan Lucas Medical Ltd.. The Journal's web site is located at http://www.agh.sanlucasmedical.com/About_the_Journal-120-
dc.relation.ispartofThe Annals of Gastroenterology & Hepatologyen_US
dc.subjectHepatitis B-
dc.subjectLamivudine-
dc.subjectHepatitis B virus (HBV) DNA-
dc.subjectHepatitis B e antigen (HBeAg)-
dc.subjectAntiviral-
dc.titleLamivudine therapy for chronic hepatitis Ben_US
dc.typeArticleen_US
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=2043-0221&volume=1&spage=000&epage=&date=2010&atitle=Lamivudine+therapy+for+chronic+hepatitis+Ben_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailFung, J: jfung@hkucc.hku.hken_US
dc.identifier.emailYuen, RMF: mfyuen@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityYuen, RMF=rp00479en_US
dc.identifier.hkuros213668en_US
dc.identifier.hkuros174079-
dc.identifier.volume1en_US
dc.identifier.issue1-
dc.identifier.spage63en_US
dc.identifier.epage70en_US
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats